These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38272562)

  • 21. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma.
    Yu Z; Li Y; Li Y; Zhang J; Li M; Ji L; Tang Y; Zheng Y; Sheng J; Han Q; Li F; Guo J; Wang L; Sun X; Gao Y; Feng H
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.
    Feng Y; Liu L; Li J; Huang J; Xie JH; Menard L; Shi Y; Zhao X; Xie S; Zang W; Tan H; Yang Z; Ni L
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
    Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
    Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.
    Dai Z; Wang Y; Sun N; Zhang C
    Front Immunol; 2023; 14():1299953. PubMed ID: 38274805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
    Chen J; Gao G; Zhang Y; Dai P; Huang Y
    BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
    Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
    Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
    Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Murai H; Kodama T; Maesaka K; Tange S; Motooka D; Suzuki Y; Shigematsu Y; Inamura K; Mise Y; Saiura A; Ono Y; Takahashi Y; Kawasaki Y; Iino S; Kobayashi S; Idogawa M; Tokino T; Hashidate-Yoshida T; Shindou H; Miyazaki M; Imai Y; Tanaka S; Mita E; Ohkawa K; Hikita H; Sakamori R; Tatsumi T; Eguchi H; Morii E; Takehara T
    Hepatology; 2023 Jan; 77(1):77-91. PubMed ID: 35567547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma.
    Wang J; Zhang X; Ma X; Chen D; Cai M; Xiao L; Li J; Huang Z; Huang Y; Lian Y
    J Exp Clin Cancer Res; 2023 Nov; 42(1):303. PubMed ID: 37968706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy.
    Peng ZP; Liu XC; Ruan YH; Jiang D; Huang AQ; Ning WR; Jiang ZZ; Zheng L; Wu Y
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
    Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
    Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune index: A gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma.
    Cui X; Han L; Cui L; Fu G; Liu E; Wang D; Song B; Zhang Y; Zhou W; Wang H; Fu J
    Pharmacol Res; 2023 Jan; 187():106583. PubMed ID: 36574578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.